Novo Nordisk ( (NVO) ) has issued an update.
Novo Nordisk has announced that its Annual General Meeting will be held on March 27, 2025, in a partially electronic format, allowing shareholders to participate either in person or virtually. The meeting will address key agenda items such as the re-election of board members, approval of the remuneration for the Board of Directors, and proposals for share repurchase and capital increase. This meeting is significant for stakeholders as it outlines the company’s governance and strategic direction, impacting its operational and market positioning.
More about Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. The company focuses on defeating serious chronic diseases, particularly through its pioneering work in diabetes treatment. Novo Nordisk employs approximately 76,300 people across 80 countries and markets its products in around 170 countries. Its B shares are listed on Nasdaq Copenhagen, and its ADRs are listed on the New York Stock Exchange.
YTD Price Performance: 2.32%
Average Trading Volume: 8,768,796
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $400.8B
See more data about NVO stock on TipRanks’ Stock Analysis page.